Results 81 to 90 of about 22,003 (134)

Identification of Plasma Biomarkers for B7 Family Members Associated With Primary Sjögren's Syndrome. [PDF]

Immun Inflamm Dis
Song S, Yang Y, Shen Y, Ren T, Sun Z, Liu C.   +5 more
europepmc   +1 more source

Investigating the activation of the immune response by outer membrane vesicles from Bacteroides fragilis using a human gastrointestinal cell system. [PDF]

J Immunol
Jefferis TM, Scano C, Ashraf A, Stevens DM, Sevcik A, Bruce E, Greathouse L, Sayes CM.   +7 more
europepmc   +1 more source

Immunological mechanisms and antibody-drug conjugates targeting B7-H3 and B7-H4 in ovarian cancer. [PDF]

Front Immunol
Brown EF, Colombo I, Madariaga A, Kasherman L.   +3 more
europepmc   +1 more source

A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4. [PDF]

Theranostics
Kim RK, Heo CK, Choi MJ, Kahm YJ, Kim MK, Lee M, Lee JY, Park H, Jung U, Shin BC, Kim BJ, Kim SC, Cho EW, Ryu CJ, Kim IG.   +14 more
europepmc   +1 more source

The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy. [PDF]

J Exp Clin Cancer Res
Hussein OJ, Rayan M, Matarid TR, Elkhalifa D, Abunada HH, Therachiyil L, Khalil A, Uddin S, Maccalli C, Korashy HM.   +9 more
europepmc   +1 more source

Enhanced renal ischemia/reperfusion injury repair potential of exosomes derived from B7-H1^high mesenchymal stem cells. [PDF]

Front Genet
He J, Yao Y, Wang R, Liu Y, Wan X, Wang H, Zhou Y, Wang W, Ma Y, Lv X.   +9 more
europepmc   +1 more source

Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy. [PDF]

Immunotargets Ther
Liu Q, Li L, Nian S, Sun X, Guo X, Li C, Yang Z, Ye Y, Yuan Q.   +8 more
europepmc   +1 more source

Discrepant CD3+ TILs in PD-L1-Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy. [PDF]

Am J Case Rep
Sekiya M, Nakatsugawa M, Koyama N, Kajiwara N, Aoki T.   +4 more
europepmc   +1 more source

Moving beyond cytotoxicity in cancer immunotherapy: embracing tumor microenvironment remodeling for durable control. [PDF]

Br J Cancer
Koelsch N, Manjili MH.
europepmc   +1 more source

Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment. [PDF]

NPJ Precis Oncol
Marchesi S, Marinello A, Ambrosini P, Cavalli C, Lo Russo G, Occhipinti M.   +5 more
europepmc   +1 more source